63 results about "Respiratory virus" patented technology

The application discloses a method for producing pectin oligosaccharides by microbial degradation of pomace and application thereof. The method comprises the following steps: adding microbacterium A5 to a culture medium containing pomace to perform fermentation to obtain a fermentation liquor, performing fractional pressing filtration and filter sterilization on the fermentation liquor, performing ethanol precipitation to extract a pectin crude product, removing protein, performing ion exchange chromatography, dialysis desalting, freeze drying and the like to purify two pectin oligosaccharides POS-1 and POS-2 with a purity greater than 95%; the pectin oligosaccharides POS-1 and POS-2 have strong scavenging capacity on hydroxyl radicals and DPPH free radicals and the capacity of inhibiting the activity of respiratory RNA viruses such as influenza virus H1N1 and respiratory syncytial virus RSV, and can be applied to medicines or health foods.

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The present application relates to the technical field of nucleic acid detection, in particular to a RNA pathogen chemiluminescence detection method based on nucleic acid structure and sequence characteristics. The present application provides a pathogen RNA rapid detection technology based on the reporter molecule cyclization combined with rolling circle amplification according to the secondary structure and sequence characteristics of RNA, which is suitable for high-sensitivity and high-specificity detection of RNA pathogens such as respiratory viruses. The present application innovatively combines the target structure characteristics with sequence specificity, breaks through the traditional sequence-dependent isothermal amplification technology, realizes the highly specific reporter molecule cyclization, significantly improves the detection reliability, and does not require complex instruments. After the swab sample is collected, the pathogen RNA is rapidly released by using a nucleic acid releasing agent, without complex purification steps, and the reading can be realized through a common chemiluminescence instrument, which is suitable for primary site detection.

Some aspects of the disclosure relate to vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses as well as methods of using the vaccines. Also described are combination vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses and other respiratory viruses (e.g., respiratory syncytial viruses and coronaviruses), as well as methods of using the vaccines.

Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and / or preventing conditions such as, for example, those caused by any viral family causing respiratory viral disease, including specifically coronaviruses and influenza viruses.

The invention relates to the technical field of nucleic acid detection, in particular to an RNA pathogen chemiluminescence detection method based on a nucleic acid structure and sequence characteristics. The invention provides a pathogen RNA rapid detection technology which is based on RNA secondary structure and sequence characteristic reporter molecule cyclization and is combined with rolling circle amplification, and is suitable for high-sensitivity and high-specificity detection of RNA pathogens such as respiratory viruses. Target structure characteristics and sequence specificity are creatively combined, a traditional sequence-dependent isothermal amplification technology is broken through, high-specificity reporter molecule cyclization is achieved, the detection reliability is remarkably improved, complex instruments are not needed, after swab samples are collected, pathogen RNA is rapidly released through a nucleic acid releasing agent, complex purification steps are not needed, and the method is suitable for large-scale popularization and application. And reading can be realized through a common chemiluminiscence instrument, and the method is suitable for base-level field detection.

The invention relates to a quinoline triazole compound and application thereof. The quinoline triazole compound has the structural characteristics as shown in formula I, and can effectively treat diseases caused by respiratory viruses such as influenza.

The application relates to the field of microorganism detection, in particular to a respiratory virus rapid detection kit based on ZIF-8 material and a preparation method, wherein the kit comprises a virus collecting device, an exhalation cylinder and a ZIF-8 membrane, the ZIF-8 membrane is detachably arranged in the exhalation cylinder, the ZIF-8 membrane comprises a chitosan layer, the chitosan layer is uniformly distributed with ZIF-8 material, virus particles in the exhaled gas of a tester through the exhalation cylinder are adsorbed, a sample processing device comprises a processing liquid, the processing liquid elutes and lyses the virus particles adsorbed by the ZIF-8 material distributed on the chitosan layer, and a virus processing liquid is obtained, a detection reagent is used for detecting the virus processing liquid and giving a detection result, sampling is simple and rapid, the detection can be completed without the participation of professionals, sampling efficiency is higher, and the detection sensitivity is effectively improved.

The invention belongs to the technical field of biology, and discloses a monoclonal antibody capable of simultaneously recognizing multiple pedigree of porcine reproductive and respiratory syndrome virus GP5 protein. The invention discloses a recombinant protein. The recombinant protein is formed by repeatedly connecting two short peptides in series. The GP5 protein is a basis for dividing a PRRSV pedigree, the GP5 protein is taken as a research object, two regions with relatively strong immunogenicity on amino acid of the GP5 protein are repeatedly connected in series, and the two regions are further connected in series with a tag sequence or a Foldon oligopeptide to obtain a recombinant protein. The recombinant protein is used as an immunogen, and a monoclonal antibody capable of simultaneously identifying GP5 proteins of a plurality of pedigree (including pedigree 1, pedigree 3, pedigree 5 and pedigree 8) of PRRSV is prepared and screened.

The invention relates to a method and equipment for rapidly killing respiratory viruses by spatially spraying hydroxyl free radical droplets, and the method comprises the following steps: introducing oxygen O2 into an oxygen plasma generation source, and applying high-frequency and high-voltage excitation to the oxygen plasma generation source to generate high-concentration oxygen active particles; oxygen active particle gas is injected into the jet mixer, a large number of ultra-fine bubbles are generated through the water jet cavitation effect, OH is efficiently generated at the instant high temperature and high pressure of explosion of the ultra-fine bubbles and under the action of pressure shock waves of backfilling holes, and then the OH flows into the second-stage baffling mixing and dissolving device to generate a high-concentration OH solution; the OH solution is sheared by high-pressure jet flow of the spray head to form OH liquid drops, and the liquid drops are contacted, collided, broken and spread to instantly kill pathogenic microorganisms including respiratory viruses; the intelligent control system performs real-time state sensing and intelligent control, fault diagnosis, prediction and early warning, cloud service and remote monitoring.

The utility model discloses a medical cotton swab portable storage device which comprises a main body box, an avoiding hole is formed in the top face of the main body box, medical cotton swabs used for screening and collecting respiratory viruses can be conveniently carried through a storage assembly, when the medical cotton swabs need to be used, a second baffle plate is pushed, and the medical cotton swabs can be conveniently stored. A single cotton swab can be pushed out from the interior of the main body box by pushing a pushing frame, and after the pushed-out cotton swab is taken out, a second baffle plate and the pushing frame are reset immediately, so that the other medical cotton swabs are prevented from being polluted after being in contact with other articles; the cotton swabs subjected to screening and collecting can be put into the isolation box by pulling the isolation plate, and the cotton swabs in the isolation box can be shielded and isolated by pushing the isolation plate through a fourth spring after the isolation plate is loosened, so that the situation that the cotton swabs carrying viruses make contact with other objects, and consequently secondary infection is caused is avoided.

The invention provides a sensor for multichannel respiratory virus impedance detection and a detection method thereof. The synchronous detection of four respiratory viruses by the single-electrode chip is realized by electrodepositing nano-gold particles on the surface of a screen-printed carbon electrode and constructing a carboxyl self-assembled single layer, and fixing different virus specific antibodies on the surfaces of different working electrodes by adopting EDC / NHS (Ethylene Diamine Chloride / N-Hydroxysuccinimide). And recording an electrochemical impedance spectrum by using a red oxidation-reduction probe, and carrying out quantitative analysis based on total impedance change. The method has the advantages of high sensitivity, strong specificity, short detection period, low cost, suitability for on-site rapid screening and the like.

The present disclosure relates to methods for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject in need thereof, the method comprising administering to the subject an anti-Type I interferon (anti-T1i) therapy that blocks the activity, function or production of Type I interferon (T1i) in the subject, wherein the anti-T1i therapy is administered to the subject infected with a respiratory virus that causes a delayed T1i response in the subject.

The invention relates to a pediatric respiratory tract infection rapid diagnosis device. By setting a clinical manifestation database of various children respiratory diseases, data can be filled into the database according to external clinical manifestations of various children under different respiratory viruses; and the specific child respiratory tract infection virus type is determined through preliminary clinical manifestation data symptom judgment and further saliva detection, so that the diagnosis rhythm is accelerated, and the diagnosis accuracy is improved.

The invention discloses a noninvasive respiratory virus aerosol enrichment detection device. The noninvasive respiratory virus aerosol enrichment detection device comprises a mouthpiece type aerosol collection interface and a rear-end filter, a thick round pipe section, a contraction conical pipe section and a thin round pipe section are sequentially connected in the blowing nozzle type aerosol collecting connector, the rear-end filter is arranged on the outer wall of the thin round pipe section in a sleeved mode, an annular protrusion is arranged on the inner wall of the middle section of the rear-end filter, and one end of the rear-end filter is fixedly connected to the outer wall of the upper end of the thin round pipe section. The tail end of the thin round pipe section abuts against the annular protrusion, the filter at the rear end is blocked by a composite activated carbon protection layer, and the upper end of the thin round pipe section is blocked by non-woven fabric; the micro-fluidic enrichment module integrated with the nano-porous detection membrane is arranged between the composite activated carbon protection layer and the non-woven fabric in the thin round pipe section, and an enriched sample output by the micro-fluidic enrichment module is communicated with the detection interface, so that a high-sensitivity detection tool is provided for prevention and control of respiratory infectious diseases, and dual requirements of timeliness and universality are met.

This application relates to the field of pharmaceutical technology, specifically disclosing a self-sampling mouthwash wash composition, a self-sampling mouthwash wash, and its application. The self-sampling mouthwash wash composition, based on the self-sampling mouthwash wash composition, comprises 0.1–2.5 wt% sodium hexadecyl sulfonate, 0.05–1.0 wt% guanidine derivative, and 0.05–1.0 wt% amino derivative. The raw materials of the self-sampling mouthwash wash include the self-sampling mouthwash wash composition. The application of the self-sampling mouthwash wash in oral self-collection of respiratory viruses. This application improves the elution ability of respiratory viruses, bacteria, and other pathogenic microorganisms in the oral cavity during self-sampling.

The invention relates to an immunogenic formulation that confers protection against respiratory viruses which comprises an attenuated recombinant strain of Bacillus Calmette and Guerin (BCG), in a concentration of between 104 109 bacteria, which expresses at least one immunogenic protein or fragment of the respiratory syncytial virus (RSV). And to the use of this immunogenic formulation to prepare a vaccine to prevent, treat, or attenuate infections of respiratory viruses, especially hRSV and / or hMPV.

This invention belongs to the field of ferret health examination technology, and particularly relates to an integrated method and device for ferret respiratory virus challenge and dynamic body fluid sampling. It includes: a base plate with a sliding groove inside, a telescopic plate slidably installed within the sliding groove, support arms fixedly installed on both sides of the base plate and the telescopic plate, an arc-shaped plate fixedly installed at the top of each support arm, a sponge pad fixedly installed on the inner side of the arc-shaped plate, a clamping plate rotatably installed on the top of the arc-shaped plate, a second sponge pad fixedly installed on the inner side of the clamping plate, a protrusion fixedly installed on the arc-shaped plate, a sliding groove inside the protrusion, symmetrically sliding limit blocks installed within the sliding groove, one end of each limit block abutting against the clamping plate, and a spring fixedly installed between the two limit blocks. This invention has a wide range of applications, allowing for rapid adjustment of the device length and support arm spacing according to the height and size of the ferret, adapting to different sizes of experimental ferrets, effectively reducing animal stress and injury, and providing convenient, safe, and reliable fixation operation.

According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention discloses a respiratory virus specimen detection device, and relates to the technical field of virus detection, the respiratory virus specimen detection device comprises a detection mechanism, the detection mechanism comprises a bottom plate, the bottom surface of the bottom plate is fixedly connected with four support legs, and a partition mechanism is arranged above the bottom plate; the partition mechanism comprises a sealing detection unit, the sealing detection unit is arranged above the bottom plate, the sealing detection unit is used for detecting respiratory virus specimens in a closed environment, and the partition mechanism further comprises an automatic discharging unit. The test paper and the specimen tube are positioned in the closed space, so that the sealing protection effect of the respiratory virus specimen detection device is improved, a respiratory virus specimen solution is prevented from emitting viruses to air when dropping on the test paper for detection, and medical personnel in a laboratory are prevented from being infected by the viruses; and the use safety and reliability of the respiratory virus specimen detection device are improved.

The use of cellular microparticles in the treatment of respiratory viral pneumonia has been disclosed. Tumor cell-derived microparticles (MPs) include cellular vesicles released by apoptotic tumor cells. The cellular vesicles express spike protein-binding receptors on their surfaces. MPs have high biosafety. In addition, it has been found that the receptors on the surface of microparticles have virus adsorption ability, and macrophages can efficiently take up MPs, which can be used to treat viral pneumonia.

The invention relates to the field of biological medicine, and particularly discloses an RSV-influenza combined vaccine and application thereof. The RSV-influenza combined vaccine comprises a respiratory syncytial virus mRNA vaccine and an influenza vaccine, the respiratory syncytial virus mRNA vaccine also comprises lipid nanoparticles, and the mRNA is loaded in the lipid nanoparticles. The RSV-influenza combined vaccine is used for preventing infection of various respiratory viruses (RSV virus and influenza virus), and the LNP adjuvant of the RSV mRNA vaccine can greatly increase the immune response of the influenza vaccine and enhance the protection efficiency of the influenza vaccine in immunocompromised people.

The invention discloses a device for collecting exhaled air condensate and a respiratory virus home detection method, the device comprises a main body, the main body comprises a semiconductor refrigeration module, an airflow channel at least partially arranged in the semiconductor refrigeration module, and a disposable unit detachably connected to an inlet of the airflow channel; a label-free electrochemical sensor for receiving the exhaled air condensate sample from the body; and the analysis module is an application program loaded on electronic equipment, a machine learning algorithm is built in the analysis module, and the analysis module is in communication connection with the unmarked electrochemical sensor and is configured to receive the electric signals of the unmarked electrochemical sensor and perform automatic analysis, comparison and result output. According to the invention, rapid, stable and non-invasive sample collection without pre-cooling can be realized, and rapid detection of respiratory viruses can be completed in a home environment.

The invention provides an anti-virus medical mask and a preparation method and application thereof.The anti-virus medical mask comprises at least one filter layer, and a virus inactivation polymer coating is anchored to the surface of the filter layer through covalent bonds; the virus inactivation polymer is formed by polymerizing a (methyl) acrylamide monomer containing a tertiary amine group or a (methyl) acrylate monomer containing a tertiary amine group and a cross-linking agent containing a long alkyl hydrophobic chain segment. The medical mask can rapidly inactivate respiratory viruses, is safe and durable, keeps good air permeability, and can be used for daily protection of respiratory viruses or clinical environment protection.

Provided in the present invention are a method and a kit for multiple detection of respiratory virus nucleic acids, and in particular, disclosed are a method, a primer, a probe and a kit for detecting a plurality of influenza A viruses such as H1N1(2019), H3N2, H5N1, H1N1 and H7N9, influenza B viruses such as Yamagata and Victoria, 2019-nCoV OFR1ab and N genes, and human internal standard gene GAPDH on the basis of a real-time fluorescent quantitative PCR technical platform.

The invention discloses a respiratory virus inactivation data-driven modeling prediction control method, which relates to the technical field of biological medicine, and comprises the following steps: acquiring initial virus characteristic data from a virus surface structure database through molecular dynamics simulation, and processing to obtain a structure change matrix of viruses under different inactivation conditions; performing feature extraction on virus characteristics and antibody binding sites by adopting a support vector machine classifier according to the structure change matrix, and determining a potential unexpected interaction site set; according to the respiratory virus inactivation data-driven modeling prediction control method, the scientificity and stability of inactivation process parameter determination are effectively improved, the safety risk caused by improper inactivation conditions is reduced, the process optimization period is shortened, the experiment cost is reduced, the good immune effectiveness is maintained while the virus inactivation safety is guaranteed, and the method is suitable for popularization and application. Therefore, the practical application requirements in vaccine research and development and virus prevention and control can be better met.

The present application relates to a kind of Houttuynia cordata polysaccharide in the use of preparation for preventing and treating virus-bacterial co-infection pneumonia and enteritis drug, HCP and uniform polysaccharide HCPM are prepared from Houttuynia cordata total polysaccharide HCP and isolated, and HCP and uniform polysaccharide HCPM of Houttuynia cordata total polysaccharide HCP are used for preparation for preventing and treating influenza virus H1N1-resistant bacteria MRSA co-infection induced lung injury and intestinal injury, and respiratory virus-bacterial co-infection drug.Compared with prior art, the present application provides a new use of Houttuynia cordata polysaccharide, and it has important value to the research and development of new drug for resisting virus-bacterial co-infection.

To provide a vaccine composition against respiratory viruses such as PIV1.SOLUTION: A variant of wild-type PIV1F proteins, wherein the variant comprises a F1 polypeptide and a F2 polypeptide, and the variant comprises at least one amino acid mutation relative to the amino acid sequence of the wild-type PIV1F proteins; Amino acid mutations provide an immunogenic composition comprising a mutant of a wild-type PIV1F protein, or a nucleic acid comprising a coding sequence of said mutant, wherein the mutant is selected from the group consisting of: (1) at least one engineered disulfide bond mutation; (2) at least one cavity-fill mutation; (3) at least one proline substitution mutation; (4) at least one glycine replacement mutation; and (5) a cleavage site mutation.SELECTED DRAWING: Figure 1

The application belongs to the technical field of targeted adenovirus, and particularly relates to a nanobody specifically combined with adenovirus Fiber protein and application thereof, and the nanobody 252A7, an amino acid sequence of which is shown as SEQ ID NO. 2. The nanobody 252A7 provided by the application can specifically recognize and combine with Fiber proteins of various serotypes of adenovirus (such as HAdV-3, HAdV-4, HAdV-7, HAdV-55), solves the technical bottleneck that traditional antibodies are difficult to recognize the conserved epitope of Fiber protein and lack broad spectrum, can effectively distinguish adenovirus from other common respiratory viruses (such as RSV, SARS-CoV-2), avoids cross reaction, and improves the accuracy and reliability of clinical etiology diagnosis. The nanobody of the application can be used for developing high-sensitivity immunological detection reagents (such as ELISA, immunochromatography, chemiluminescence, etc.), and has potential application value in the fields of targeted therapy and molecular imaging.

A non-infectious bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.